Ainos, Inc. (NASDAQ:AIMD – Get Free Report) was the recipient of a large decline in short interest during the month of February. As of February 27th, there was short interest totaling 83,517 shares, a decline of 15.8% from the February 12th total of 99,130 shares. Based on an average daily trading volume, of 51,598 shares, the short-interest ratio is presently 1.6 days. Approximately 1.9% of the company’s stock are sold short. Approximately 1.9% of the company’s stock are sold short. Based on an average daily trading volume, of 51,598 shares, the short-interest ratio is presently 1.6 days.
Analyst Ratings Changes
Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Ainos in a report on Monday, December 29th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.
Check Out Our Latest Research Report on AIMD
Insider Buying and Selling
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently modified their holdings of the company. Mariner LLC acquired a new position in shares of Ainos during the 4th quarter worth about $37,000. Two Sigma Investments LP bought a new stake in shares of Ainos in the 3rd quarter valued at about $80,000. DRW Securities LLC raised its holdings in shares of Ainos by 272.6% in the 4th quarter. DRW Securities LLC now owns 66,211 shares of the company’s stock valued at $109,000 after purchasing an additional 48,439 shares during the period. Finally, Renaissance Technologies LLC raised its holdings in shares of Ainos by 13.1% in the 4th quarter. Renaissance Technologies LLC now owns 66,300 shares of the company’s stock valued at $109,000 after purchasing an additional 7,700 shares during the period.
Ainos Price Performance
NASDAQ:AIMD opened at $1.41 on Monday. The stock has a market capitalization of $6.78 million, a PE ratio of -0.35 and a beta of 2.39. Ainos has a 1-year low of $1.26 and a 1-year high of $4.50. The firm has a fifty day simple moving average of $1.73 and a 200 day simple moving average of $2.54. The company has a current ratio of 2.96, a quick ratio of 2.67 and a debt-to-equity ratio of 1.10.
About Ainos
Ainos, Inc (NASDAQ: AIMD) is a clinical‐stage biopharmaceutical company dedicated to developing inhalation therapies for patients with chronic pulmonary disorders. The company’s proprietary platform centers on a dry powder inhalation technology designed to deliver therapeutic agents directly to the lungs, potentially improving drug distribution and reducing systemic side effects compared to traditional oral or intravenous formulations.
The lead product candidate, AI‐401, is an inhaled formulation of ibuprofen in a dry powder format.
Featured Stories
- Five stocks we like better than Ainos
- The $8,000 Gold Call Every Retirement Saver Needs to Read Right Now
- A personal warning from Martin Weiss (Please read)
- Elon Musk: This Could Turn $100 into $100,000
- ~$1.5T SpaceX IPO: Pre-IPO Opportunity
- America’s gold reserves are priced at $42. The real price is $6,000+.
Receive News & Ratings for Ainos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ainos and related companies with MarketBeat.com's FREE daily email newsletter.
